SCHEMBL895556

SCHEMBL895556

CC(C)(C)OC(=O)N(CC(=O)O)c1ccc(O)cc1

nearest known ligand 0.40

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 2/20 0.39
CYP3A4 P08684 2/20 0.38
ALDH1A1 P00352 1/20 0.38
ESR1 P03372 1/20 0.38
ESR2 Q92731 1/20 0.38
MIF P14174 1/20 0.36
MEN1 O00255 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL219603 0.87 SMN1; SMN2 (0.49) MLYCDCYP3A4ALDH1A1MEN1CYP2C9
SCHEMBL1826174 0.86 MLYCD (0.44) MLYCDALDH1A1MIF
SCHEMBL266144 0.86 MT-CO2 (0.46) MLYCDCYP3A4ALDH1A1MIFMEN1
SCHEMBL2929114 0.86 MLYCD (0.38) MLYCDMEN1KMT2ASMN1; SMN2
SCHEMBL11648528 0.86 MLYCD (0.38) MLYCDCYP3A4MEN1CYP2C9CYP2C19
SCHEMBL3349318 0.86 MLYCD (0.41) MLYCDMEN1KMT2A
SCHEMBL3375082 0.86 MLYCD (0.38) MLYCDCYP3A4MEN1CYP2C9CYP2C19
SCHEMBL11052501 0.86 NQO2 (0.39) MEN1CYP2C9KMT2A
SCHEMBL3660817 0.85 KEAP1 (0.49)
SCHEMBL8333179 0.85 CA12 (0.41) MLYCDALDH1A1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0593615-B1 AROMATIC COMPOUNDS, COMPOSITIONS CONTAINING THEM AND THEIR USE IN THERAPY MERCK SHARP & DOHME (GB) 1996-01-31 EP claimed
JP-61040291-A None JP disclosed
EP-1427423-B9 BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA ASTRAZENECA AB (SE) 2017-12-20 EP disclosed
US-9364424-B2 Topical cosmetic skin lightening compositions and methods of use thereof STIEFEL LABORATORIES, INC. (US) 2016-06-14 US disclosed
US-20160074315-A1 TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF STIEFEL LABORATORIES, INC. 2016-03-17 US disclosed
US-8907092-B2 Inhibitors of IAP GENENTECH, INC. (US) 2014-12-09 US disclosed
US-8586542-B2 Small molecule apoptosis promoters JOYANT PHARMACEUTICALS, INC. (US) 2013-11-19 US disclosed
US-20130281385-A1 SMALL MOLECULE APOPTOSIS PROMOTERS JOYANT PHARMACEUTICALS, INC. 2013-10-24 US disclosed
US-8222291-B2 Small molecule apoptosis promoters JOYANT PHARMACEUTICALS, INC. (US) 2012-07-17 US disclosed
US-20120082640-A1 Small molecule apoptosis promoters JOYANT PHARMACEUTICALS, INC. 2012-04-05 US disclosed
US-4013764-A PHARMACEUTICAL COMPOSITIONS COMPRISING SUBSTITUTED PHENYLGLYCYLCEPHALOSPORINS AND METHODS OF TREATING BACTERIAL INFECTIONS SMITHKLINE CORPORATION (US) 1977-03-22 US disclosed
US-3987041-A P-HYDROXYMETHYLPHENYLACETAMIDOCEPHALOSPORINS SMITHKLINE CORPORATION (US) 1976-10-19 US disclosed
US-3985739-A 3-Heterocyclic thiomethylcephalosporins SMITHKLINE CORPORATION (US) 1976-10-12 US disclosed
US-3972919-A CHEMICAL INTERMEDIATE FOR ANTIBIOTICS SMITHKLINE CORPORATION (US) 1976-08-03 US disclosed
US-3968226-A 3-Heterocyclic thiomethylcephalosporins as antibacterial agents SMITHKLINE CORPORATION (US) 1976-07-06 US disclosed
US-3962230-A BACTERICIDES SMITHKLINE & FRENCH LABORATORIES, INC. (US) 1976-06-08 US disclosed
US-3957768-A BACTERICIDES SMITHKLINE CORPORATION (US) 1976-05-18 US disclosed
US-3953439-A ANTIBACTERIAL SMITHKLINE CORPORATION (US) 1976-04-27 US disclosed
US-3946005-A BACTERICIDES SMITHKLINE CORPORATION (US) 1976-03-23 US disclosed
US-3943129-A BACTERICIDE SMITHKLINE CORPORATION (US) 1976-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281385-A1 SMALL MOLECULE APOPTOSIS PROMOTERS BID, BAD, BAX MLYCD 1009/4885CYP3A4 4868/4885ALDH1A1 4619/4885
US-20120082640-A1 Small molecule apoptosis promoters BID, BAD, BAX MLYCD 1009/4885CYP3A4 4868/4885ALDH1A1 4619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.